Clinical trial
Phase III Trial in Acute Promyelocytic Leukemia Patients
NCT00482833 · Gruppo Italiano Malattie EMatologiche dell'Adulto, Other · Completed
Key facts
| NCT number | NCT00482833 |
|---|---|
| Title | Phase III Trial in Acute Promyelocytic Leukemia Patients |
| Official title | A Randomised Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA Versus Standard ATRA and Anthracycline-Based Chemotherapy (AIDA Regimen) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia |
| Acronym | APL0406 |
| Lead sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto, Other |
| Collaborators | Study Alliance Leukemia (SAL) Group |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | arsenic trioxide, idarubicin, mercaptopurine, methotrexate, all-trans retinoic acid, all-trans retinoic acid (ATRA) |
| Enrollment | 276 |
| Start date | Aug 1, 2007 |
| Primary completion | Sep 1, 2012 |
| Completion | Oct 17, 2019 |
| First posted | Jun 5, 2007 |
| Last update posted | Oct 12, 2022 |
| Countries | Austria, Germany, Italy |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: